Internal Medicine, Medical Oncology · New York, NY
NPI
1972761294
Since 2008
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
1275 York Ave
New York, NY, 10065
Phone (646) 422-4631
Groups this clinician bills Medicare through
Medicare paid, 2024
$63K
761 services
Medicare patients, 2024
139
Average age 72
Drug cost, 2024
$6.1M
822 prescriptions
Company payments, 2025
$12K
From 6 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Martin H Voss was code 99214 (office e&m - established), 406 times for 95 patients. In total Martin H Voss billed 761 services in 15 codes, and Medicare paid $63K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-04-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 406 | 95 | $87.43 | $35K |
| 99215 Office E&M - Established | Office | 113 | 48 | $130.84 | $15K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 108 | 58 | $14.32 | $1,547 |
| 99213 Office E&M - Established | Office | 59 | 41 | $56.56 | $3,337 |
| 99204 Office E&M - New | Office | 17 | 17 | $121.92 | $2,073 |
By year: 2022 $56K for 591 services; 2023 $53K for 619 services; 2024 $63K for 761 services.
Medicare prescription drug claims, 2024
In 2024, the drug Martin H Voss prescribed most often to Medicare patients was Cabometyx (Cabozantinib S-Malate), with 121 prescriptions and refills. In total Martin H Voss wrote 822 Medicare prescriptions that cost $6.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Cabometyx Cabozantinib S-Malate | 121 | 121 | 22 | $2.3M |
| Lenvima Lenvatinib Mesylate | 102 | 102 | 20 | $2.3M |
| Levothyroxine Sodium Generic | 66 | 136 | 20 | $789 |
| Prednisone Generic | 49 | 49 | 15 | $139 |
| Pantoprazole Sodium Generic | 47 | 95 | 13 | $483 |
| Everolimus Generic | 43 | 43 | Under 11 | $138K |
| Amlodipine Besylate Generic | 37 | 81 | 16 | $248 |
| Triamcinolone Acetonide Generic | 31 | 32 | 15 | $196 |
| Welireg Belzutifan | 29 | 29 | Under 11 | $667K |
| Dexamethasone Sodium Phosphate Generic | 27 | 27 | Under 11 | $309 |
| Inlyta Axitinib | 24 | 24 | Under 11 | $365K |
| Hydrochlorothiazide Generic | 17 | 39 | Under 11 | $96.82 |
| Olanzapine Generic | 13 | 19 | Under 11 | $112 |
| Ondansetron Hcl Generic | 13 | 13 | Under 11 | $95.46 |
| Omeprazole Generic | 13 | 33 | Under 11 | $204 |
Brand drugs: 329 claims; generic drugs: 493 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Martin H Voss $12K ($12K in general payments such as food, travel and fees) from 6 companies. The largest payer was Eisai Inc. with $8,548.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.